Homepage Top Section 2

Cabotegravir is indicated for use in high-risk adults and adolescents aged a minimum of 12 years weighing at least 35 kg. It is claimed to be the first

Under the agreement, Synaffix will be eligible for an upfront payment, milestone payments along with tiered royalties on net sales of resulting products. The company will also produce

The provisional approval comes with a duration of two years. It is based on the data from Phase II studies that enrolled highly sensitised patients who received imlifidase

As per the terms of the deal, OEP will receive exclusive rights from OncoVent to commercialise oregovomab in Taiwan. The licence will also cover related regulatory applications and

ENHERTU, which is a HER2 directed ADC, features a HER2 monoclonal antibody attached to a topoisomerase I inhibitor payload through a stable tetrapeptide-based cleavable linker. The approval of

The vaccine candidate seeks to prevent anthrax in people after suspected or confirmed exposure to Bacillus anthracis. AV7909 is being assessed in adult persons between 18 and 65

Biotech company Immunai has raised $215m in Series B funding round to accelerate the development of its immune-first drug actuary platform. Koch Disruptive Technologies led the funding round